Centre moves to simplify medical device regulations

1. At a Glance

• Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017 to cut regulatory duplication and speed up market access for eligible medical devices [1].
• Reforms target three areas: outsourced sterilisation licensing, uniform testing fees, and expansion of countries recognised for clinical investigation waivers [3].
• Reflects the broader Ease of Doing Business (EoDB) push while retaining a traceability safeguard (label disclosure) [1][3].
• Relevant for GS-II (governance, health policy) and GS-III (indigenisation, med-tech industry).

2. Why in the News

• On Monday, 24 August 2026, the Health Ministry issued a release announcing proposed amendments to Rule 44 (sterilisation licensing) and Rule 63 (clinical investigation waiver jurisdictions) of the Medical Devices Rules, 2017 [1][3].
• Reported by The Hindu on 25 August 2026 [4] and multiple outlets same week [1][2][3].

3. Background & Evolution

• Medical Devices Rules, 2017 notified under the Drugs and Cosmetics Act, 1940, brought medical devices under a dedicated regulatory framework distinct from pharmaceuticals, administered via CDSCO (Central Drugs Standard Control Organisation) under the Health Ministry.
• Earlier, manufacturers outsourcing sterilisation had to obtain a separate loan licence even when the sterilisation facility itself already held a valid licence — a long-standing industry grievance cited as duplicative [4][1].
• Rule 63 previously recognised USA, UK, Australia, Canada, and Japan as "stringent regulatory jurisdictions" whose approvals could waive clinical investigation requirements for devices without predicate devices in India [3].
• Current amendment proposes adding the European Union to this list [3].

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• Reduces compliance costs and paperwork for manufacturers lacking in-house sterilisation infrastructure, aiding smaller/med-tech startups [4][1].
• Faster market access via expanded waiver jurisdictions lowers time-to-market for imported/EU-approved devices [3].

Administrative/Governance

• Removes duplicative dual-licensing (device manufacturer + sterilisation facility both separately licensed) — a classic regulatory-overlap fix [4].
• Traceability retained via mandatory label disclosure, balancing deregulation with patient safety oversight [4][1].

Regulatory/Legal

• Amendment operates via rule-making power under the Drugs and Cosmetics Act, 1940 (delegated legislation), not fresh statute.
• Expanding recognised "stringent regulatory jurisdictions" is a reliance-based regulatory harmonisation tool, aligning India with global regulatory equivalence practices [3].

Industry/Strategic

• Signals intent to make India more attractive for medical device manufacturing and imports, supporting "Make in India" and self-reliance narratives alongside easier global-approval leverage [1][3].

6. Recent Developments (last 12-18 months)

• 24 August 2026: Health Ministry release proposing amendments to Rules 44 and 63 of Medical Devices Rules, 2017 [1][3].
• 25 August 2026: Reported in The Hindu print edition (International/Main edition, Page 6) [4].
• Proposal includes standardisation of testing fees, alongside the sterilisation and waiver-jurisdiction changes [3].

7. Prelims Hooks

• Medical Devices Rules, 2017 are framed under the Drugs and Cosmetics Act, 1940.
• Nodal body for medical device regulation: CDSCO, under the Ministry of Health and Family Welfare.
• Rule 44 deals with outsourced sterilisation licensing; Rule 63 deals with waiver of clinical investigation requirements.
• Countries currently recognised under Rule 63 for waiver: USA, UK, Australia, Canada, Japan; proposed addition — European Union.
• Manufacturers outsourcing sterilisation to an already-licensed facility will no longer need a separate loan licence.
• Traceability retained: sterilisation facility's licence number must be printed on the device label.
• Transition period for compliance with new labelling: 6 months.
• Amendments announced via ministry release dated 24 August 2026.
• Objective stated: balance regulatory oversight with ease of doing business.
• One additional reform component: standardisation of testing fees across the sector.

8. Mains Relevance

• GS-II: Government policies and interventions in health sector; issues relating to health infrastructure and regulation.
• GS-III: Indigenisation of technology, ease of doing business, industry-regulation interface in med-tech/manufacturing.
• Possible question stems: 1. "Examine how regulatory simplification in the medical devices sector can balance ease of doing business with patient safety. Discuss with reference to recent amendments to the Medical Devices Rules, 2017." 2. "India's reliance on foreign regulatory approvals (US, UK, EU, etc.) for waiving clinical trials of medical devices — discuss the rationale, benefits, and risks of such regulatory equivalence mechanisms." 3. "Critically analyse the evolution of medical device regulation in India from the Drugs and Cosmetics Act, 1940 to the Medical Devices Rules, 2017."

9. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940 — parent statute enabling these rules.
• CDSCO and drug regulatory architecture in India — institutional context.
• New Drugs and Clinical Trials Rules, 2019 — parallel regulatory reform track for pharma [S3 search context].
• Ease of Doing Business rankings and India's regulatory reform agenda — broader policy linkage.
• Make in India / PLI scheme for medical devices — manufacturing ecosystem tie-in.
• National Medical Devices Policy, 2023 — sectoral policy framework.
• Regulatory harmonisation / mutual recognition agreements — comparative global regulatory practice.

10. Common Errors / Trap Areas

• Don't confuse Medical Devices Rules, 2017 with the Drugs and Cosmetics Rules, 1945 — devices now have a distinct, though Act-linked, framework.
• Don't attribute this to NITI Aayog or DPIIT — it is a Health Ministry/CDSCO action, though it serves EoDB goals often associated with DPIIT.
• Rule 63 waiver jurisdictions are not all G7/G20 — only USA, UK, Australia, Canada, Japan (+ proposed EU); do not assume China or others are included.
• The reform removes a licence requirement, it does not remove testing/labelling obligations — traceability via label disclosure is explicitly retained.
• These are proposed amendments (draft/announced), not yet confirmed as final notified rules as of the source date — avoid stating them as already in force.